All Stories

  1. Poor reliability in measuring habituation: Implications for clinical and translational research on exposure and extinction
  2. Navigating the Complexities of Treatment-Resistant Depression in Late Life
  3. A deep-learning based biomarker of systemic cellular senescence burden to predict mortality and health outcomes
  4. High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID‐19 Treatment
  5. Major depressive disorder as a driver of premature aging
  6. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
  7. Comparing Treatment Approaches for Older Adults with Treatment-Resistant Depression -- The OPTIMUM Study
  8. Design and feasibility of an Alzheimer’s disease blood test study in a diverse community-based population
  9. Fatness, fitness and the aging brain: A cross sectional study of the associations between a physiological estimate of brain age and physical fitness, activity, sleep, and body composition
  10. Using Implementation Science to Guide the Process of Adapting a Patient Engagement Intervention for Inpatient Spinal Cord Injury/Disorder Rehabilitation
  11. Mindfulness Training for Depressed Older Adults Using Smartphone Technology: Protocol for a Fully Remote Precision Clinical Trial
  12. Optimized, personalized, and digitalized: protocol for a fully-remote precision clinical trial of mindfulness training for depressed older adults using smartphone technology (Preprint)
  13. Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
  14. Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
  15. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
  16. Perioperative Mental Health in Older Adults: New Research on Epidemiology and Outcomes
  17. Smartphone-Based Ecological Momentary Assessment as the New Standard Measure for Post-Stroke Functioning (Preprint)
  18. Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial
  19. Comparing stress prediction models using smartwatch physiological signals and participant self-reports
  20. Effect of electroencephalogram-guided anaesthesia administration on 1-yr mortality: follow-up of a randomised clinical trial
  21. Ketamine for Depression in Older Adults
  22. Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial
  23. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
  24. Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: An Observational Multicenter Study
  25. Postictal generalized electroencephalographic suppression following electroconvulsive therapy: Temporal characteristics and impact of anesthetic regimen
  26. Surgical Complications in Older Adults Predict Decline in Self-Perceived Cognitive Function in the Ensuing Year: A Cohort Study
  27. Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time
  28. Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study
  29. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
  30. Executive Function Moderates Functional Outcomes of Engagement Strategies During Rehabilitation in Older Adults
  31. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
  32. COVID-19 Clinical Trials: A Voice From the Front Lines
  33. Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy
  34. Going remote: Implementing digital research methods at an academic medical center during COVID-19
  35. Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders
  36. Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression
  37. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
  38. Voltage-based automated detection of postictal generalized electroencephalographic suppression: Algorithm development and validation
  39. A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment
  40. iTBS to Relieve Depression and Executive Dysfunction in Older Adults: An Open Label Study
  41. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases
  42. The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults
  43. A Qualitative Study of Perioperative Depression and Anxiety in Older Adults
  44. Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders
  45. Effectiveness of theory-based digital self-management interventions for improving depression, anxiety, fatigue and self-efficacy in people with neurological disorders: A systematic review and meta-analysis
  46. Pharmacological Treatments for Tinnitus—Reply
  47. Experiences of American Older Adults with Pre-existing Depression During the Beginnings of the COVID-19 Pandemic: A Multicity, Mixed-Methods Study
  48. Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults
  49. Effectiveness of non-pharmacological interventions for treating post-stroke depressive symptoms: Systematic review and meta-analysis of randomized controlled trials
  50. Positive information facilitates response inhibition in older adults only when emotion is task-relevant
  51. Older molecular brain age in severe mental illness
  52. Stereoselective Steady‐State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults
  53. Mindfulness, Education, and Exercise for age-related cognitive decline: Study protocol, pilot study results, and description of the baseline sample
  54. Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease
  55. Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial
  56. Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions
  57. Preoperative Cognitive Abnormality, Intraoperative Electroencephalogram Suppression, and Postoperative Delirium
  58. Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine
  59. Central-positive complexes in ECT-induced seizures: Evidence for thalamocortical mechanisms
  60. Mood Disorders and Dementia: Time for Action
  61. mHealth Assessment and Intervention of Depression and Anxiety in Older Adults
  62. “What Were You Before the War?” Repurposing Psychiatry During the COVID-19 Pandemic
  63. Action at a Distance: Geriatric Research during a Pandemic
  64. Precision Medicine in Clinical Trials
  65. Does patient expectancy account for the cognitive and clinical benefits of mindfulness training in older adults?
  66. Tinnitus
  67. A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment (Preprint)
  68. Activity Level and Intensity of Older Adults in Skilled Nursing Rehabilitation Measured via Actigraphy
  69. Neuroticism predicts fear of falling after hip fracture
  70. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease
  71. Predicting Remission in Late-Life Major Depression
  72. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis
  73. A qualitative study of older adults’ perspectives on initiating exercise and mindfulness practice
  74. Comorbid anxiety in late‐life depression: Relationship with remission and suicidal ideation on venlafaxine treatment
  75. Cognitive Training for Optimizing Perioperative Brain Health
  76. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized
  77. Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study
  78. Obsessions are strongly related to eating disorder symptoms in anorexia nervosa and atypical anorexia nervosa
  79. Effect of Enhanced Medical Rehabilitation on Functional Recovery in Older Adults Receiving Skilled Nursing Care After Acute Rehabilitation
  80. Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole
  81. Antidepressant Treatment for Late‐Life Depression: Considering Risks and Benefits
  82. An inverse relationship between cortical plasticity and cognitive inhibition in late-life depression
  83. Emotional Response Inhibition Is Greater in Older Than Younger Adults
  84. Feasibility of Intensive Ecological Sampling of Tinnitus in Intervention Research
  85. When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials
  86. Pride and Prejudice in the Treatment of Depression and Anxiety in Acutely Ill Older Adults
  87. Diagnostic, clinical, and personality correlates of food anxiety during a food exposure in patients diagnosed with an eating disorder
  88. Crossover to Bilateral Repetitive Transcranial Magnetic Stimulation
  89. Effect of Electroencephalography-Guided Anesthetic Administration on Postoperative Delirium Among Older Adults Undergoing Major Surgery
  90. Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial
  91. Assessment and treatment of major depression in older adults
  92. Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
  93. Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
  94. Cognitive Improvement in Older Adults in the Year After Hip Fracture: Implications for Brain Resilience in Advanced Aging
  95. Pharmacogenetic Guidelines and Decision Support Tools for Depression Treatment: Application to Late-Life
  96. Assessment of neuroplasticity in late-life depression with transcranial magnetic stimulation
  97. Scientific Biography of a Mid-Career Physician-Scientist: Getting by With Help From My Friends
  98. Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia
  99. Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression
  100. Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial
  101. Meal and snack-time eating disorder cognitions predict eating disorder behaviors and vice versa in a treatment seeking sample: A mobile technology based ecological momentary assessment study
  102. Reduced GABAergic cortical inhibition in aging and depression
  103. Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol
  104. Ability of postoperative delirium to predict intermediate-term postoperative cognitive function in patients undergoing elective surgery at an academic medical centre: protocol for a prospective cohort study
  105. Childhood Trauma Is Associated With Poorer Cognitive Performance in Older Adults
  106. Cognitive Training for Older Adults: What Works?
  107. Integrative Geriatric Psychiatry
  108. Depression and Functional Impairment: A Pernicious Pairing in Older Adults
  109. Electroencephalography-Guided Minimisation of Anaesthetic Administration to Prevent Post-Operative Delirium: A Randomised, Pragmatic Trial
  110. The role of late life depressive symptoms on the trajectories of insomnia symptoms during antidepressant treatment
  111. Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance
  112. Achieving Milestones as a Prerequisite for Proceeding With a Clinical Trial
  113. Alternative Facts? Antidepressants and Falls in Older Adults
  114. Fear of food prospectively predicts drive for thinness in an eating disorder sample recently discharged from intensive treatment
  115. Effects of Cable News Watching on Older Adults’ Physiological and Self-Reported Stress and Cognitive Function
  116. The role of depression pharmacogenetic decision support tools in shared decision making
  117. Specific depressive symptoms predict remission to aripiprazole augmentation in late‐life treatment resistant depression
  118. Mindfulness-Based Stress Reduction for Older Adults With Stress Disorders and Neurocognitive Difficulties
  119. Potentially Inappropriate Medications and the Time to Full Functional Recovery After Hip Fracture
  120. Evaluation of Ecological Momentary Assessment for Tinnitus Severity
  121. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
  122. Plasma REST: a novel candidate biomarker of Alzheimer’s disease is modified by psychological intervention in an at-risk population
  123. Bone Turnover with Venlafaxine Treatment in Older Adults with Depression
  124. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults
  125. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders
  126. Predictors of Posttraumatic Stress Symptoms and Association with Fear of Falling After Hip Fracture
  127. Fear of Falling after Hip Fracture: Prevalence, Course, and Relationship with One-Year Functional Recovery
  128. Enhanced Medical Rehabilitation: Effectiveness of a clinical training model
  129. Telephone-Delivered Stepped Collaborative Care for Treating Anxiety in Primary Care: A Randomized Controlled Trial
  130. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder
  131. Consequences of Anxiety in Aging and Cognitive Decline
  132. Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation
  133. Older Adults' Perspectives on Clinical Research: A Focus Group and Survey Study
  134. Gray matter regions statistically mediating the cross‐sectional association of eotaxin and set‐shifting among older adults with major depressive disorder
  135. Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression
  136. Unreliability as a threat to understanding psychopathology: The cautionary tale of attentional bias.
  137. Immunological biomarkers associated with brain structure and executive function in late‐life depression: exploratory pilot study
  138. Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) study: a pragmatic, randomised clinical trial
  139. Treatment Emergent Suicidal Ideation in depressed older adults
  140. Use of the Temperament and Character Inventory to Predict Response to Repetitive Transcranial Magnetic Stimulation for Major Depression
  141. Feasibility and Acceptability of Smartphone Assessment in Older Adults with Cognitive and Emotional Difficulties
  142. Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial.
  143. Ecological momentary assessment versus standard assessment instruments for measuring mindfulness, depressed mood, and anxiety among older adults
  144. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression
  145. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial
  146. Trajectories of depressive symptoms after hip fracture
  147. Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences
  148. Trajectories of suicidal ideation in depressed older adults undergoing antidepressant treatment
  149. Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial
  150. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial
  151. Solving the Geriatric Mental Health Crisis in the 21st Century
  152. Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults
  153. Cause or Effect? Selective Serotonin Reuptake Inhibitors and Falls in Older Adults: A Systematic Review
  154. Response to Stubbs's Letter to the Editor
  155. Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment
  156. Treating Anxiety Disorders in Older Adults
  157. A new measure of fear of falling: psychometric properties of the fear of falling questionnaire revised (FFQ-R)
  158. <span style="font-variant:small-caps; ">d</span>-Cycloserine Facilitation of Exposure Therapy Improves Weight Regain in Patients With Anorexia Nervosa
  159. Clarifying the Behavioral Economics of Social Anxiety Disorder
  160. Effect of Physical Activity, Social Support, and Skills Training on Late-Life Emotional Health: A Systematic Literature Review and Implications for Public Health Research
  161. Association of Functional Polymorphisms from Brain-Derived Neurotrophic Factor and Serotonin-Related Genes with Depressive Symptoms after a Medical Stressor in Older Adults
  162. Response to Mohler and Colleagues
  163. Effects of Mindfulness Based Stress Reduction Therapy on Subjective Bother and Neural Connectivity in Chronic Tinnitus
  164. Ecological Momentary Assessment of Tinnitus Using Smartphone Technology
  165. A Novel Treatment for Tinnitus and Tinnitus-Related Cognitive Difficulties Using Computer-Based Cognitive Training and D-Cycloserine
  166. Short-term affective recovery from hip fracture prospectively predicts depression and physical functioning.
  167. Common Selective Serotonin Reuptake Inhibitor Side Effects in Older Adults Associated with Genetic Polymorphisms in the Serotonin Transporter and Receptors: Data from a Randomized Controlled Trial
  168. How bandwidth selection algorithms impact exploratory data analysis using kernel density estimation.
  169. Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults
  170. Development and Testing of Treatments
  171. Planning Grants
  172. Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review
  173. Combiningd-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke
  174. Patient Active Time During Therapy Sessions in Postacute Rehabilitation: Development and Validation of a New Measure
  175. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone
  176. Mindfulness-based stress reduction for older adults with worry symptoms and co-occurring cognitive dysfunction
  177. Dynamic Prediction of Treatment Response in Late-Life Depression
  178. Is There a Role for Antidepressant and Antipsychotic Pharmacogenetics in Clinical Practice in 2014?
  179. Validation of the Ambivalent and Purposeful Engagement – Trait Measure
  180. Anxiety Disorders
  181. Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults
  182. Anxiety Disorders in Older Adults: Looking to DSM5 and Beyond…
  183. Antidepressant Medication Augmented With Cognitive-Behavioral Therapy for Generalized Anxiety Disorder in Older Adults
  184. Research to Reduce the Suicide Rate Among Older Adults: Methodology Roadblocks and Promising Paradigms
  185. Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder
  186. Lessons Learned Fromd-Cycloserine: The Promise and Limits of Drug Facilitation of Exposure Therapy
  187. Enhanced Medical Rehabilitation Is Feasible in a Skilled Nursing Facility: Preliminary Data on a Novel Treatment for Older Adults With Depression
  188. Serotonin–norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption
  189. A HIGH-THROUGHPUT CLINICAL ASSAY FOR TESTING DRUG FACILITATION OF EXPOSURE THERAPY
  190. Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial
  191. Functional network dysfunction in anxiety and anxiety disorders
  192. Measuring Treatment Fidelity in a Rehabilitation Intervention Study
  193. Reversal of SSRI-Associated Urinary Retention With Mirtazapine Augmentation
  194. Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors
  195. Comorbid anxiety and depression: bête noire or quick fix?
  196. Memantine for late‐life depression and apathy after a disabling medical event: a 12‐week, double‐blind placebo‐controlled pilot study
  197. Inflammatory Cytokine Levels and Depressive Symptoms in Older Women in the Year After Hip Fracture: Findings from the Baltimore Hip Studies
  198. Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder
  199. Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group
  200. Treatment‐related alteration of cortisol predicts change in neuropsychological function during acute treatment of late‐life anxiety disorder
  201. Elevated Cortisol in Older Adults With Generalized Anxiety Disorder Is Reduced by Treatment: A Placebo-Controlled Evaluation of Escitalopram
  202. Treating Depression in Older Adults with Dementia
  203. Anxiety Disorders: New Developments in Old Age
  204. Altered cerebral blood flow patterns associated with pathologic worry in the elderly
  205. Maintenance Treatment of Depression in Old Age
  206. Relation of Serotonin Transporter Genetic Variation to Efficacy of Escitalopram for Generalized Anxiety Disorder in Older Adults
  207. Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study
  208. Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management
  209. Anxiety disorders in older adults: a comprehensive review
  210. Cognitive and Affective Predictors of Rehabilitation Participation After Stroke
  211. Use of the Late‐Life Function and Disability Instrument to Assess Disability in Major Depression
  212. Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers
  213. fMRI activation in late‐life anxious depression: a potential biomarker
  214. Apathy After Hip Fracture: A Potential Target for Intervention to Improve Functional Outcomes
  215. The Burden of Late-Life Generalized Anxiety Disorder: Effects on Disability, Health-Related Quality of Life, and Healthcare Utilization
  216. Escitalopram Treatment of Generalized Anxiety Disorder in Older Adults—Reply
  217. Patient Participation and Physical Activity During Rehabilitation and Future Functional Outcomes in Patients After Hip Fracture
  218. Aripiprazole Prescribing Patterns and Side Effects in Elderly Psychiatric Inpatients
  219. High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression
  220. Pilot Study of Augmentation With Aripiprazole for Incomplete Response in Late-Life Depression
  221. Escitalopram for Older Adults With Generalized Anxiety Disorder
  222. The utility of the Generalized Anxiety Disorder Severity Scale (GADSS) with older adults in primary care
  223. Association of serotonin-1A and 2A receptor promoter polymorphisms with depressive symptoms and functional recovery in elderly persons after hip fracture
  224. Generalized Anxiety Disorder Severity Scale Validation in Older Adults
  225. Do Clinical Rehabilitation Education Programs Really Improve Stroke-Related Knowledge?
  226. Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in late‐life anxiety disorders
  227. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder
  228. Rescue Pharmacotherapy With Duloxetine for Selective Serotonin Reuptake Inhibitor Nonresponders in Late-Life Depression
  229. An Open-Label Pilot Study of Acetylcholinesterase Inhibitors to Promote Functional Recovery in Elderly Cognitively Impaired Stroke Patients
  230. Residual symptoms and recurrence during maintenance treatment of late-life depression
  231. Biomarkers in Geriatric Psychiatry
  232. Stroke-Related Knowledge and Health Behaviors Among Poststroke Patients in Inpatient Rehabilitation
  233. Maintenance Treatment for Old‐Age Depression Preserves Health‐Related Quality of Life: A Randomized, Controlled Trial of Paroxetine and Interpersonal Psychotherapy
  234. Depressive symptoms in late life: associations with apathy, resilience and disability vary between young‐old and old‐old
  235. Preventing Depression in Medical Illness
  236. Cognitive Impairment in Late-Life Generalized Anxiety Disorder
  237. Recovery From Major Depression in Older Adults Receiving Augmentation of Antidepressant Pharmacotherapy
  238. Predicting 6‐week treatment response to escitalopram pharmacotherapy in late‐life major depressive disorder
  239. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study
  240. Does depression, apathy or cognitive impairment reduce the benefit of inpatient rehabilitation facilities for elderly hip fracture patients?
  241. Onset of Depression in Elderly Persons After Hip Fracture: Implications for Prevention and Early Intervention of Late‐Life Depression
  242. Impact of Prior Treatment Exposure on Response to Antidepressant Treatment in Late Life
  243. The Relationship Between Pain and Mental Flexibility in Older Adult Pain Clinic Patients
  244. Influence of Rehabilitation Site on Hip Fracture Recovery in Community-Dwelling Subjects at 6-Month Follow-Up
  245. Maintenance Treatment of Major Depression in Old Age
  246. Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment
  247. Evidence-Based Treatment of Geriatric Anxiety Disorders
  248. Predictors of Adequacy of Depression Management in the Primary Care Setting
  249. Dr. Lenze and Colleagues Reply
  250. Conclusions Inconsistent With Results With Citalopram
  251. Somatic symptoms of depression in elderly patients with medical comorbidities
  252. Comorbid anxiety disorder in late life depression: association with memory decline over four years
  253. Somatic Symptoms in Late-Life Anxiety: Treatment Issues
  254. Association of the Serotonin Transporter Gene-Linked Polymorphic Region (5-HTTLPR) Genotype With Depression in Elderly Persons After Hip Fracture
  255. The Course of Functional Decline in Older People with Persistently Elevated Depressive Symptoms: Longitudinal Findings from the Cardiovascular Health Study
  256. Effect of rehabilitation site on functional recovery after hip fracture
  257. Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial
  258. Generalized Anxiety Disorder in Late Life: Lifetime Course and Comorbidity With Major Depressive Disorder
  259. Significance of poor patient participation in physical and occupational therapy for functional outcome and length of stay
  260. Adverse effects of depression and cognitive impairment on rehabilitation participation and recovery from hip fracture
  261. The Pittsburgh Rehabilitation Participation Scale: reliability and validity of a clinician-rated measure of participation in acute rehabilitation
  262. Time Course of Response to Antidepressants in Late-Life Major Depression
  263. Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety
  264. Good treatment outcomes in late-life depression with comorbid anxiety
  265. Treatment Considerations for Anxiety in the Elderly
  266. Poster 74
  267. Comorbidity of depression and anxiety in the elderly
  268. Anxiety Disorders in Late Life: An Evolving Picture
  269. Risk Factors for Falls During Treatment of Late-Life Depression
  270. Clinically Relevant Behaviors in Elderly Hip Fracture Inpatients
  271. Effect of Cerebrovascular Risk Factors on Depression Treatment Outcome in Later Life
  272. Combined Pharmacotherapy and Psychotherapy as Maintenance Treatment for Late-Life Depression: Effects on Social Adjustment
  273. Anxiety Symptoms in Elderly Patients with Depression
  274. Subjective health measures and acute treatment outcomes in geriatric depression
  275. The Association of Late-Life Depression and Anxiety With Physical Disability: A Review of the Literature and Prospectus for Future Research
  276. Comorbidity of depression and anxiety disorders in later life
  277. Comorbid Anxiety Disorders in Depressed Elderly Patients
  278. White Matter Hyperintensities and Gray Matter Lesions in Physically Healthy Depressed Subjects
  279. Psychiatric Symptoms Endorsed by Somatization Disorder Patients in a Psychiatric Clinic
  280. Reactivation of Latent Herpes Simplex Virus by Excimer Laser Photokeratectomy